이화정(李和姃) 교수

약학과[대학원] /약학부 /제약산업학과[대학원]

이화정 프로필 사진
이화정 교수는 대학원 약학과/약학대학 약학과 교수로 생물약제학과 약물동태학 분야 전문가이다. 미국 버팔로 뉴욕주립대학교 약학대학 약제학부에서 박사학위를 받았으며, 신약 및 개량신약의 약물동태학, 배출수송체 저해제 발굴 등의 연구를 수행하고 있다. 현재까지 SCI급 국제전문학술지에 약 90여편, 국내전문학술지에 약 20여편의 논문을 게재하였다.
  • 약학관 B동 102호
  • 02-3277-3409
  • 면담 가능시간
    • 수 14:00-16:00
연구실적
  • Development of an Ephedrine In-House Matrix Reference Material and Its Application to Doping Analysis ACS OMEGA, 2024, v.9 no.11, 12689-12697
    SCIE Scopus dColl.
  • BEAR: A Novel Virtual Screening Method Based on Large-Scale Bioactivity Data JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2023, v.63 no.5
    SCIE Scopus dColl.
  • COVID-19 drugs: potential interaction with ATP-binding cassette transporters P-glycoprotein and breast cancer resistance protein Journal of Pharmaceutical Investigation, 2023, v.53 no.2, 191-212
    SCIE Scopus KCI dColl.
  • Digestive enzyme supplementation in prescription drugs, over-the-counter drugs, and enzyme foods Journal of Pharmaceutical Investigation, 2023, v.53 no.3, 343-355
    SCIE Scopus KCI dColl.
  • Interrupting specific hydrogen bonds between ELF3 and MED23 as an alternative drug resistance-free strategy for HER2-overexpressing cancers Journal of Advanced Research, 2023, v.47, 173-187
    SCIE Scopus dColl.
  • Population pharmacokinetics and model-based dosing optimization of teicoplanin in elderly critically ill patients with pneumonia Journal of Critical Care, 2023, v.78, 154402
    SCIE Scopus dColl.
  • Development and evaluation of a digestive formulation using a microbial enzyme for treatment of dyspepsia Journal of Pharmaceutical Investigation, 2022, v.52 no.5, 601-609
    SCIE Scopus KCI dColl.
  • Discovery of (E)-3-(3-((2-Cyano-4' -dimethylaminobiphenyl-4-ylmethyl)cyclohexanecarbonylamino)-5-fluorophenyl)acrylic Acid Methyl Ester, an Intestine-Specific, FXR Partial Agonist for the Treatment of Nonalcoholic Steatohepatitis JOURNAL OF MEDICINAL CHEMISTRY, 2022, v.65 no.14, 9974-10000
    SCIE Scopus dColl.
  • Discovery of a NADPH oxidase inhibitor, (E)-3-cyclohexyl-5-(4-((2-hydroxyethyl)(methyl)amino)benzylidene)-1-methyl-2-thioxoimidazolidin-4-oneone, as a novel therapeutic for Parkinson's disease European Journal of Medicinal Chemistry, 2022, v.244, 114854
    SCIE Scopus dColl.
  • Drug-like small molecule HSP27 functional inhibitor sensitizes lung cancer cells to gefitinib or cisplatin by inducing altered cross-linked Hsp27 dimers Pharmaceutics, 2021, v.13 no.5, 630
    SCIE Scopus dColl.
  • Dual Inhibition of P-gp and BCRP Improves Oral Topotecan Bioavailability in Rodents PHARMACEUTICS, 2021, v.13 no.4, 559
    SCIE Scopus dColl.
  • Optimization, validation, and comparison of a rapid method for the quantification of insulin-like growth factor 1 in serum using liquid chromatography–high-resolution mass spectrometry Drug Testing and Analysis, 2021, v.13 no.2, 451-459
    SCIE Scopus dColl.
  • Quantification of teicoplanin using the hplc-uv method for clinical applications in critically ill patients in Korea Pharmaceutics, 2021, v.13 no.4, 572
    SCIE Scopus dColl.
  • Structural Requirements of 1-(2-Pyridinyl)-5-pyrazolones for Disproportionation of Boronic Acids MOLECULES, 2021, v.26 no.22, 6814
    SCIE Scopus dColl.
  • Design of a Novel Theranostic Nanomedicine (III): Synthesis and Physicochemical Properties of Tumor-Targeting Cisplatin Conjugated to a Hydrophilic Polyphosphazene INTERNATIONAL JOURNAL OF NANOMEDICINE, 2020, v.15, 981-990
    SCIE Scopus dColl.
  • Synthesis, biological evaluation and molecular modelling of 2,4-disubstituted-5-(6-alkylpyridin-2-yl)-1H-imidazoles as ALK5 inhibitors JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2020, v.35 no.1, 702-712
    SCIE Scopus dColl.
  • Effects of Piperazine Derivative on Paclitaxel Pharmacokinetics PHARMACEUTICS, 2019, v.11 no.1, 23
    SCIE Scopus dColl.
  • Pharmacokinetic Study of NADPH Oxidase Inhibitor Ewha-18278, a Pyrazole Derivative PHARMACEUTICS, 2019, v.11 no.9, 482
    SCIE Scopus dColl.
  • Pharmacokinetic alteration of paclitaxel by ferulic acid derivative Pharmaceutics, 2019, v.11 no.11, 593
    SCIE Scopus dColl.
  • Emergence of synthetic mRNA: In vitro synthesis of mRNA and its applications in regenerative medicine BIOMATERIALS, 2018, v.156, 172-193
    SCIE Scopus dColl.
  • Intestinal P-glycoprotein inhibitors, benzoxanthone analogues JOURNAL OF PHARMACY AND PHARMACOLOGY, 2018, v.70 no.2, 234-241
    SCIE Scopus dColl.
  • Menopausal hormone therapy and the risk of breast cancer by histological type and race: a meta-analysis of randomized controlled trials and cohort studies BREAST CANCER RESEARCH AND TREATMENT, 2018, v.170 no.3, 667-675
    SCIE Scopus dColl.
  • Regulation of endogenic metabolites by rosuvastatin in hyperlipidemia patients: An integration of metabolomics and lipidomics CHEMISTRY AND PHYSICS OF LIPIDS, 2018, v.214, 69-83
    SCIE Scopus dColl.
  • Design of theranostic nanomedicine (II): synthesis and physicochemical properties of a biocompatible polyphosphazene-docetaxel conjugate INTERNATIONAL JOURNAL OF NANOMEDICINE, 2017, v.12
    SCIE Scopus dColl.
  • Effects of Adamantyl Derivatives on Pharmacokinetic Behavior of Paclitaxel in Rats BIOMOLECULES & THERAPEUTICS, 2017, v.25 no.5, 553-558
    SCIE Scopus KCI dColl.
  • Rational design, synthesis, and evaluation of novel 2,4-Chloro- and Hydroxy-Substituted diphenyl Benzofuro[3,2-b]Pyridines: Non-intercalative catalytic topoisomerase I and II dual inhibitor European Journal of Medicinal Chemistry, 2017, v.127, 318-333
    SCIE Scopus dColl.
  • Sensitization of lung cancer cells by altered dimerization of HSP27 Oncotarget, 2017, v.8 no.62, 105372-105382
    SCIE Scopus dColl.
  • 1H-Nuclear magnetic resonance-based metabolic profiling of nonsteroidal anti-inflammatory drug-induced adverse effects in rats Journal of Pharmaceutical and Biomedical Analysis, 2016, v.129, 492-501
    SCIE Scopus dColl.
  • A novel pyrazole derivative protects from ovariectomy-induced osteoporosis through the inhibition of NADPH oxidase SCIENTIFIC REPORTS, 2016, v.6, 22389
    SCIE Scopus dColl.
  • Design of a novel theranostic nanomedicine: Synthesis and physicochemical properties of a biocompatible Polyphosphazene–platinum(II) conjugate International Journal of Nanomedicine, 2016, v.11, 837-851
    Scopus dColl.
  • Development of simultaneous analysis of tryptophan metabolites in serum and gastric juice - an investigation towards establishing a biomarker test for gastric cancer diagnosis Biomedical Chromatography, 2016, 12 July 2016
    SCIE Scopus dColl.
  • Effective Killing of Cancer Cells Through ROS-Mediated Mechanisms by AMRI-59 Targeting Peroxiredoxin I ANTIOXIDANTS & REDOX SIGNALING, 2016, v.24 no.8, 453-469
    SCIE Scopus dColl.
  • Effective killing of cancer cells and regression of tumor growth by K27 targeting sulfiredoxin Free Radical Biology and Medicine, 2016, v.101, 384-392
    SCIE Scopus dColl.
  • Sulfiredoxin inhibitor induces preferential death of cancer cells through reactive oxygen species-mediated mitochondrial damage Free Radical Biology and Medicine, 2016, v.91, 264-274
    SCIE Scopus dColl.
  • Xanthone analogues as potent modulators of intestinal P-glycoprotein EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2015, v.93, 237-245
    SCIE Scopus dColl.
  • Development of lipidomic platform and phosphatidylcholine retention time index for lipid profiling of rosuvastatin treated human plasma JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2014, v.944, 157-165
    SCIE Scopus dColl.
  • Discovery of N-((4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197) : A Highly Potent, Selective, and Orally Bioavailable Inhibitor of TGF-beta Type I Receptor Kinase as Cancer Immunotherapeutic/Antifibrotic Agent JOURNAL OF MEDICINAL CHEMISTRY, 2014, v.57 no.10, 4213-4238
    SCIE Scopus dColl.
  • Effect of coumarin derivative-mediated inhibition of P-glycoprotein on oral bioavailability and therapeutic efficacy of paclitaxel EUROPEAN JOURNAL OF PHARMACOLOGY, 2014, v.723, 381-388
    SCIE Scopus dColl.
  • Na+/H+ Exchanger Regulatory Factor 3 Is Critical for Multidrug Resistance Protein 4-Mediated Drug Efflux in the Kidney JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2014, v.25 no.4, 726-736
    SCIE Scopus dColl.
  • Preclinical evaluation of efficacy and stability of docetaxel micelle-encapsulated by a tripodal cyclotriphosphazene amphiphile BIOMEDICINE & PHARMACOTHERAPY, 2014, v.68 no.5, 649-655
    SCIE Scopus dColl.
  • Synthesis and properties of a new micellar polyphosphazene-platinum(II) conjugate drug JOURNAL OF INORGANIC BIOCHEMISTRY, 2014, v.140, 45-52
    SCIE Scopus dColl.
  • Aripiprazole-montmorillonite: A new organic-inorganic nanohybrid material for biomedical applications Chemistry - A European Journal, 2013, v.19 no.15, 4869-4875
    SCIE Scopus dColl.
  • Effects of single or repeated silymarin administration on pharmacokinetics of risperidone and its major metabolite, 9-hydroxyrisperidone in rats Xenobiotica, 2013, v.43 no.3, 303-310
    SCIE Scopus dColl.
  • Identification of a New Hexenoic Acid Glycoside and the RSV Principles from Vitis vinifera cv. Muscat of Alexandria Bulletin of the Korean Chemical Society, 2013, v.34 no.6, 1906-1908
    SCIE KCI Scopus dColl.
  • In Vitro and in Vivo Evaluation of Phenylbutenoid Dimers as Inhibitors of P-Glycoprotein JOURNAL OF NATURAL PRODUCTS, 2013, v.76 no.12, 2277-2281
    SCIE Scopus dColl.
  • Synthesis and physicochemical properties of new tripodal amphiphiles bearing fatty acids as a hydrophobic group Bioorganic and Medicinal Chemistry Letters, 2013, v.23 no.6, 1763-1767
    SCIE Scopus dColl.
  • A nanohybrid system for taste masking of sildenafil International Journal of Nanomedicine, 2012, v.7, 1635-1649
    Scopus dColl.
  • Determination of daumone in mouse plasma by HPLC/MS-MS Biomedical Chromatography, 2012, v.26 no.2, 152-155
    SCIE Scopus dColl.
  • Effects of formulation on pharmacokinetics of docetaxel in rats Journal of Pharmaceutical Investigation, 2012, v.42 no.1, 51-55
    KCI Scopus dColl.
  • Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats European Journal of Pharmaceutical Sciences, 2012, v.45 no.3, 296-301
    SCIE Scopus dColl.
  • Evaluation of pharmacokinetic differences of acetaminophen in pseudo germ-free rats Biopharmaceutics and Drug Disposition, 2012, v.33 no.6, 292-303
    SCIE Scopus dColl.
  • Nuclear magnetic resonance-based metabolomics for prediction of gastric damage induced by indomethacin in rats Analytica Chimica Acta, 2012, v.722, 87-94
    SCIE Scopus dColl.
  • Preclinical study of a potent P-glycoprotein and cytochrome P450 enzyme inducer rifampicin changing pharmacokinetic parameters of risperidone and its metabolite, 9-hydroxyrisperidone, using a rat model Journal of Pharmaceutical Investigation, 2012, v.42 no.6, 345-351
    KCI Scopus dColl.
  • Quantitative analysis of acetaminophen and its six metabolites in rat plasma using liquid chromatography/tandem mass spectrometry Biomedical Chromatography, 2012, v.26 no.12, 1596-1604
    SCIE Scopus dColl.
  • Stable and efficient delivery of docetaxel by micelle-encapsulation using a tripodal cyclotriphosphazene amphiphile International Journal of Pharmaceutics, 2012, v.422 no.41276, 374-380
    SCIE Scopus dColl.
  • [학술지논문] Population pharmacokinetics and model-based dosing optimization of teicoplanin in elderly critically ill patients with pneumonia JOURNAL OF CRITICAL CARE, 2023, v.78 no.0 , 154402-154402
    SCIE
  • [지적재산권] 알콕시페닐프로펜온 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 다약제 내성 억제용 약학적 조성물 국내 : 특허, 등록, 10-1427291, 2014
강의
  • 2024-2학기

    • 생물약제학

      • 학수번호 22497분반 01
      • 4학년 ( 1.5학점 , 1.5시간) 화 3~3 (포462)
      • 전공필수
    • 생물약제학

      • 학수번호 22497분반 02
      • 4학년 ( 1.5학점 , 1.5시간) 화 5~5 (약A400)
      • 전공필수
    • 약학실습Ⅴ

      • 학수번호 37137분반 01
      • 5학년 ( 1.5학점 , 3시간) 화 6~9 (약A313)
      • 전공필수 집중이수(8주) 수업, 학번 61~80
    • 약학실습Ⅴ

      • 학수번호 37137분반 02
      • 5학년 ( 1.5학점 , 3시간) 수 6~9 (약A313)
      • 전공필수 집중이수(8주) 수업, 학번 81~100
    • 약학실습Ⅴ

      • 학수번호 37137분반 03
      • 5학년 ( 1.5학점 , 3시간) 월 6~9 (약A313)
      • 전공필수 집중이수(8주) 수업, 학번 101~120
    • 약동학

      • 학수번호 38959분반 01
      • 3학년 ( 3학점 , 3시간)
      • 원격강의 미래산업약학전공 39064-01반과 합반
    • 약동학

      • 학수번호 39064분반 01
      • 3학년 ( 3학점 , 3시간)
      • 원격강의 약학전공 38959-01반과 합반
  • 2024-1학기

    • 약제학

      • 학수번호 37134분반 03
      • 5학년 ( 1.5학점 , 1.5시간) 금 4~4 (약A104)
      • 전공필수
    • 약학실습Ⅴ

      • 학수번호 37137분반 01
      • 5학년 ( 1.5학점 , 3시간) 수 6~9 (약A313)
      • 전공필수 집중이수(8주) 수업, 학번 1~20
    • 약학실습Ⅴ

      • 학수번호 37137분반 02
      • 5학년 ( 1.5학점 , 3시간) 월 6~9 (약A313)
      • 전공필수 집중이수(8주) 수업, 학번 21~40
    • 약학실습Ⅴ

      • 학수번호 37137분반 03
      • 5학년 ( 1.5학점 , 3시간) 화 6~9 (약A313)
      • 전공필수 집중이수(8주) 수업, 학번 41~60
    • 제약및의약품행정실무실습

      • 학수번호 37153분반 01
      • 6학년 ( 2.5학점 , 160시간)
      • 전공필수
    • 산업약학입문

      • 학수번호 39045분반 01
      • 2학년 ( 1.5학점 , 1.5시간) 목 6~6 (약A100-1)
    • 임상약물동태학

      • 학수번호 G16863분반 01
      • 학년 ( 3학점 , 3시간) 화 2~3 (약)
  • 2022-2학기

    • 생물약제학

      • 학수번호 22497분반 01
      • 4학년 ( 1.5학점 , 1.5시간) 월 5~5 (약A404)
      • 전공필수
    • 생물약제학

      • 학수번호 22497분반 02
      • 4학년 ( 1.5학점 , 1.5시간) 수 3~3 (약A104)
      • 전공필수
    • 약동학

      • 학수번호 37109분반 01
      • 3학년 ( 1.5학점 , 1.5시간) 수 2~2 (약A404)
    • 약학실습Ⅴ

      • 학수번호 37137분반 01
      • 5학년 ( 1.5학점 , 3시간) 월 6~9 (약A313)
      • 전공필수 팀티칭, 학번 66~86, 집중이수(8주) 수업
    • 약학실습Ⅴ

      • 학수번호 37137분반 02
      • 5학년 ( 1.5학점 , 3시간) 화 6~9 (약A313)
      • 전공필수 팀티칭, 학번 87~108, 집중이수(8주) 수업
    • 약학실습Ⅴ

      • 학수번호 37137분반 03
      • 5학년 ( 1.5학점 , 3시간) 수 6~9 (약A313)
      • 전공필수 팀티칭, 학번 109~130, 집중이수(8주) 수업, 산업제약학과 04반과 합반
    • 약학실습Ⅴ

      • 학수번호 37137분반 04
      • 5학년 ( 1.5학점 , 3시간) 수 6~9 (약A313)
      • 전공필수 집중이수(8주) 수업, 약학과 03반과 합반
    • 심화실습및연구Ⅰ

      • 학수번호 37154분반 04
      • 6학년 ( 4학점 , 200시간)
      • 전공필수
    • 심화실습및연구Ⅲ

      • 학수번호 37156분반 02
      • 6학년 ( 4학점 , 200시간)
      • 전공필수
    • Honors research

      • 학수번호 37803분반 01
      • 4학년 ( 1학점 , 1시간)
      • 팀티칭, 산업제약학과 02반과 합반
  • 2022-1학기

    • 약제학

      • 학수번호 37134분반 03
      • 5학년 ( 1.5학점 , 1.5시간) 금 4~4 (약A400)
      • 전공필수 산업제약학과 04반과 합반
    • 약제학

      • 학수번호 37134분반 04
      • 5학년 ( 1.5학점 , 1.5시간) 금 4~4 (약A400)
      • 전공필수 추가개설/약학과 03반과 합반
    • 약학실습Ⅴ

      • 학수번호 37137분반 01
      • 5학년 ( 1.5학점 , 3시간) 월 6~7 (약A313)
      • 전공필수 팀티칭/ 학번 1~22
    • 약학실습Ⅴ

      • 학수번호 37137분반 02
      • 5학년 ( 1.5학점 , 3시간) 수 6~7 (약A313)
      • 전공필수 팀티칭/ 학번 23~43
    • 약학실습Ⅴ

      • 학수번호 37137분반 03
      • 5학년 ( 1.5학점 , 3시간) 목 6~7 (약A313)
      • 전공필수 팀티칭/ 학번 44~65
    • 제약및의약품행정실무실습

      • 학수번호 37153분반 01
      • 6학년 ( 2.5학점 , 160시간)
      • 전공필수
    • 임상약물동태학

      • 학수번호 G16863분반 01
      • 학년 ( 3학점 , 3시간) 목 2~3
  • 2021-2학기

    • 생물약제학

      • 학수번호 22497분반 01
      • 4학년 ( 1.5학점 , 1.5시간) 월 5~5
      • 전공필수
    • 생물약제학

      • 학수번호 22497분반 02
      • 4학년 ( 1.5학점 , 1.5시간) 수 3~3
      • 전공필수
    • 약동학

      • 학수번호 37109분반 01
      • 3학년 ( 1.5학점 , 1.5시간) 수 2~2
      • 산업제약학과 02반과 합반
    • 약동학

      • 학수번호 37109분반 02
      • 3학년 ( 1.5학점 , 1.5시간) 수 2~2
      • 약학과 01반과 합반
    • 약학실습Ⅴ

      • 학수번호 37137분반 01
      • 5학년 ( 1.5학점 , 3시간) 월 6~9 (약A313)
      • 전공필수 집중이수(8주) 수업, 팀티칭, 학번 66~86
    • 약학실습Ⅴ

      • 학수번호 37137분반 02
      • 5학년 ( 1.5학점 , 3시간) 화 6~9 (약A313)
      • 전공필수 집중이수(8주) 수업, 팀티칭, 학번 87~108
    • 약학실습Ⅴ

      • 학수번호 37137분반 03
      • 5학년 ( 1.5학점 , 3시간) 수 6~9 (약A313)
      • 전공필수 집중이수(8주) 수업, 팀티칭, 학번 109~130
    • 심화실습및연구Ⅰ

      • 학수번호 37154분반 04
      • 6학년 ( 4학점
      • 전공필수
    • 심화실습및연구Ⅱ

      • 학수번호 37155분반 04
      • 6학년 ( 4학점
      • 전공필수
    • 심화실습및연구Ⅲ

      • 학수번호 37156분반 02
      • 6학년 ( 4학점
      • 전공필수
  • 2021-1학기

    • 약제학

      • 학수번호 37134분반 03
      • 5학년 ( 1.5학점 , 1.5시간) 월 2~2
      • 전공필수 산업제약학과 04반과 합반
    • 약학실습Ⅴ

      • 학수번호 37137분반 01
      • 5학년 ( 1.5학점 , 3시간) 목 5~6 (약A313)
      • 전공필수 팀티칭/ 학번 1~22
    • 약학실습Ⅴ

      • 학수번호 37137분반 02
      • 5학년 ( 1.5학점 , 3시간) 월 6~7 (약A313)
      • 전공필수 팀티칭/ 학번 23~43
    • 약학실습Ⅴ

      • 학수번호 37137분반 03
      • 5학년 ( 1.5학점 , 3시간) 수 6~7 (약A313)
      • 전공필수 팀티칭/ 학번 44~65
    • 제약및의약품행정실무실습

      • 학수번호 37153분반 01
      • 6학년 ( 2.5학점
      • 전공필수
    • Honors research

      • 학수번호 37803분반 01
      • 4학년 ( 1학점 , 1시간)
      • 산업제약학과 02반과 합반
    • 실무프로젝트분석I

      • 학수번호 G16659분반 01
      • 학년 ( 3학점 , 3시간) 월 8~9
    • 임상약물동태학

      • 학수번호 G16863분반 01
      • 학년 ( 3학점 , 3시간) 수 2~3
학력

State University of New York at Buffalo Ph.D.(약제학)

이화여자대학교 약학석사(약학과)

이화여자대학교 약학사(제약학과)

경력

연구처부처장 2014-02-01 ~ 2016-01-31

산학협력단부단장 2014-02-01 ~ 2016-01-31

창업보육센터소장 2014-02-01 ~ 2015-10-31

약학대학교학부장 2011-08-01 ~ 2013-07-31